🧾 What This Document Is

This is a "Post-Qualification Amendment" to a Regulation A offering. Think of it like an update to a previously approved permission slip from the SEC. HeartSciences already got the green light in March 2025 to sell stock to the public. This filing updates that original plan with new financial statements (for the year ending April 2025 and the quarter ending January 2026) and other current information. They're still selling the same basic investment package.

👉 Why it matters: This tells investors the company's story is still ongoing and provides the freshest numbers to base an investment decision on. It's a required update, not a brand-new plan.

🏢 What The Company Does

In simple terms, HeartSciences is developing technology to make standard heart tests (ECGs) much smarter using Artificial Intelligence (AI). Their main product is a cloud-based platform called MyoVista Insights™.

• The Problem: The traditional ECG is a ubiquitous, cheap test but is limited in detecting many heart diseases early. This gap leads to overuse of expensive follow-up tests like echocardiograms ($600-$3,000) and angiograms ($5,000+).
• Their Solution: Their AI software can analyze the same ECG data to detect a wider range of conditions (like heart muscle dysfunction or valve issues) that usually require those expensive tests. Think of it as a powerful software upgrade for a basic hardware tool.
• The Business Model: They aim to sell this as a cloud-based subscription service (SaaS) to hospitals and clinics, making advanced diagnostics more accessible and cost-effective.

💰 Financial Highlights & The Ask

The company is pre-revenue and losing money, which is common for early-stage medical tech firms.

• The Fundraising Goal: They are offering up to $15 million worth of investment "Units."
• Each Unit costs $3.50 and consists of:
  1. One share of Series D Preferred Stock (which can convert to 1 share of common stock).
  2. One Warrant to buy another share of common stock at $5.00 in the future.
• Already Sold: As of this update, they've already raised $6.7 million from selling 1.9 million units under the original offering.
• Current Financial State: They have "substantial doubt" about their ability to continue as a "going concern" without more funding. This is a major red flag that signals they need this money to survive.

🚀 Recent Key Moves & Uses of Proceeds

The company is actively working to get its products to market and is using debt to stay afloat.

• Product Progress: They launched the MyoVista Insights™ platform in May 2025, got a key compatibility badge from Epic (a major healthcare software company) in March 2026, and submitted their MyoVista wavECG device to the FDA for clearance in December 2025. FDA clearance is crucial for them to start selling.
• Taking on Debt: In January 2026, they took a $3.6 million loan from Streeterville Capital. After fees, they got $3.0 million in cash. The loan has a high 12% interest rate and tough terms, including potential monthly repayments.
• Where the Money Will Go: The net proceeds from this offering (estimated at $13.95 million if the full $15M is raised) will be used for: R&D, FDA submissions, marketing, paying off debt (like the Streeterville note), and general working capital.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths:

• Addresses a huge, costly problem in healthcare.
• Their platform model could become the standard for managing ECG data and AI tools.
• They have patents and important licenses (like from Mount Sinai hospital).

⚠️ Significant Risks (This is crucial):

• No Product Revenue Yet: They don't have a cleared device or recurring sales. Their success is entirely future-dependent.
• Regulatory Hurdle: The FDA has not yet cleared their main device. Without it, they can't sell.
• Cash Burn & Going Concern: They are losing money and have explicitly said they might not survive without this funding.
• Dilution: The Units are structured to dilute existing shareholders significantly if the preferred stock converts and warrants are exercised.
• High-Cost Debt: They are using expensive loans to fund operations, which can burden the company.
• Competition: They face well-funded giants like GE Healthcare and Philips.

🔮 What's Next

The immediate future hinges on two things:

1. Successfully raising capital through this offering to fund operations.
2. Receiving FDA 510(k) clearance for their MyoVista wavECG device, which is currently under review.

If they achieve these, they plan to build sales channels, install their platform at key hospital sites, and grow their AI algorithm marketplace.

🌍 Industry Context

The market for AI in medical devices, especially for diagnostics, is exploding. Healthcare systems are desperate for tools that improve accuracy and reduce costs. However, adoption is slow due to regulatory rigor, integration challenges with existing hospital IT systems, and the need for proven clinical data. HeartSciences is trying to enter this competitive but high-potential space.

💡 Why This Matters For An Investor

This is a high-risk, speculative investment in an early-stage company. You are not investing in a proven business but in a plan. Your money will fund the race to get FDA approval and initial sales. The structure of the deal (units with warrants) also means your ownership stake could be diluted later. The "going concern" warning is the most critical flag—it means the auditors believe the company's survival is in question without significant new money.

🧠 The Analogy

Investing in HeartSciences now is like funding a team with a promising blueprint for a revolutionary solar panel. They haven't built a working prototype (FDA clearance) or sold any units yet, and they're running out of money for parts. You're buying a piece of the patent and the right to buy more of the company later at a set price, hoping they get the prototype working and can convince a big utility (a hospital system) to buy it.

🧩 Final Takeaway

This is a lifeline offering for a pre-revenue medical AI company that needs to raise cash to survive and get its core product approved by regulators. The investment carries very high risk due to the company's unproven technology, regulatory dependency, and precarious financial state.